Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Change in Inventory (2016 - 2025)

Ligand Pharmaceuticals' Change in Inventory history spans 15 years, with the latest figure at -$2.8 million for Q4 2025.

  • For Q4 2025, Change in Inventory fell 8.11% year-over-year to -$2.8 million; the TTM value through Dec 2025 reached -$5.0 million, up 48.14%, while the annual FY2025 figure was -$5.0 million, 48.14% up from the prior year.
  • Change in Inventory for Q4 2025 was -$2.8 million at Ligand Pharmaceuticals, up from -$3.6 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $13.0 million in Q2 2023 and bottomed at -$9.7 million in Q2 2022.
  • The 5-year median for Change in Inventory is -$1.6 million (2022), against an average of -$768400.0.
  • The largest annual shift saw Change in Inventory skyrocketed 872.98% in 2021 before it tumbled 4525.0% in 2023.
  • A 5-year view of Change in Inventory shows it stood at -$2.7 million in 2021, then surged by 49.33% to -$1.4 million in 2022, then skyrocketed by 47.86% to -$707000.0 in 2023, then plummeted by 262.94% to -$2.6 million in 2024, then dropped by 8.11% to -$2.8 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Change in Inventory are -$2.8 million (Q4 2025), -$3.6 million (Q3 2025), and $875000.0 (Q2 2025).